AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?

AstraZeneca (NYSE:AZN) will pay $600 million upfront for global rights to Zegfrovy, a lung cancer treatment, with potential milestones totaling $1.5 billion. The drug, approved in the U.S. and China, targets a specific mutation and showed improved survival rates in trials. AstraZeneca aims to strengthen its oncology portfolio, leveraging its existing infrastructure and global reach.

AstraZeneca lost a lawsuit against the US government over Medicare drug price negotiations. Judge Matthew J. Maddox ruled in favor of the government, upholding its eligibility criteria for price negotiations. The case involved AstraZeneca's challenge to the CMS's definition of qualifying single-source drugs.

China's IIT system faces scrutiny after undisclosed gene therapy deaths. AstraZeneca and Daiichi Sankyo's Enhertu showed promise in lung cancer trials. Tanabe Pharma to receive $435M for global rights to dermatology drug. Sandoz partners with Shanghai Henlius for biosimilars. Other biotech news includes CAR-T trial deaths, SK's settlement, and Hengrui's profit squeeze.

AstraZeneca halted the Phase III eVOLVE-Lung02 trial for volrustomig after an IDMC review found the drug unlikely to meet primary endpoints of PFS or OS in PD-L1 negative NSCLC patients. The company stated no new safety concerns were identified. AstraZeneca continues other Phase III trials for volrustomig in different cancer types. The setback follows other recent pipeline disappointments, but the company reported positive results in two other late-stage lung cancer studies.

HUTCHMED reported positive phase 3 trial results for Orpathys (savolitinib) plus Tagrisso (osimertinib) in EGFR-mutated non-small cell lung cancer. The combination showed significant improvements in progression-free and overall survival compared to chemotherapy. The study focused on patients with MET overexpression or amplification, a common resistance mechanism. HUTCHMED and AstraZeneca plan to pursue global registrations for the combination.

AstraZeneca halted the phase 3 eVOLVE-Lung02 trial of volrustomig for first-line metastatic NSCLC, as it is unlikely to meet primary endpoints. The trial compared volrustomig plus chemotherapy against pembrolizumab plus chemotherapy in patients with low PD-L1 expression. AstraZeneca will continue other trials for volrustomig in different cancers.